September 30, 2022
An end-of-week review of retina news and stories from September 24-30, 2022.
September 28, 2022
The drug’s efficacy was reported to be superior to that achieved with laser photocoagulation.
September 19, 2022
Roche’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.
September 11, 2022
Oral APX3330 was found to demonstrate favorable safety and tolerability profile in interim masked safety results, consistent with 11 prior trials of APX3330.
September 10, 2022
Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
September 08, 2022
The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.
David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.
Drs David A. Eichenbaum and Caroline Baumal discuss unmet needs in treating AMD and DME.
Retina specialists discuss how to incorporate faricimab into clinical practice and discuss implacations of the TRUCKEE study.
David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, review the dual mechanism of action of faricimab as well as the 2-year update in the TENAYA, LUCERNE, YOSEMITE, and RHINE trials.
